Cancer Archive — Page 36 of 69

January 23, 2020

HDL-cholesterol and breast cancer risk

Genetic analyses suggest that high circulating HDL-cholesterol levels may increase breast cancer risk — a surprising finding since increased HDL-cholesterol is thought to be healthy.

January 23, 2020

Study examines prostate cancer treatment decisions

A five-year follow-up study of more than 2,000 U.S. men who received prostate cancer treatment is creating a road map for future patients regarding long-term bowel, bladder and sexual function in order to clarify expectations and enable men to make informed choices about care.

x-ray of stomach
January 16, 2020

VUMC study sheds light on gastric cancer development

VUMC researchers have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development.

November 20, 2019

Study finds breast cancer recurrence score has different implications for men

A study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence. However, a new study finds this conclusion may not directly apply to male patients with the same type of breast cancer

Researchers on the NCI Moonshot grant focused on hereditary cancers include (front row, from left) Natasha Celaya-Cobbs, LPN, Georgia Wiesner, MD, Sarah Bland, MPH, MBA, (back row, from left) Trent Rosenbloom, MD, Josh Peterson, MD, MPH, and Marc Beller, PMP, BA.
November 14, 2019

NCI ‘Moonshot’ grant to boost hereditary cancer identification

VUMC is leading an initiative to establish a streamlined process for collection of family health histories that could set the stage for a standardized system to make the information easily accessible.

Charles Manning, PhD, and colleagues are working to improve the effectiveness of immunotherapies earlier in treatment.
November 7, 2019

Project seeks new way to assess immunotherapy effectiveness

GE Healthcare has awarded researchers in the Vanderbilt University Institute of Imaging Science $2.5 million in funding to develop PET tracer that will determine the effectiveness of immunotherapy in patients early in their treatment course.